- ￥1480
- EK-Bioscience
- CCC-Y4014
- 2026年01月09日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
vero E6、vero E6、vero E6细胞、vero E6细胞、vero E6非洲绿猴肾细胞
Cell line name Vero C1008
Synonyms VERO C1008; VeroC1008; VEROC1008; VERO C 1008; VERO C1008 (E6); Vero 76 clone E6; Vero 76 clone E-6; Vero E-6; Vero E6; VERO E6; Vero-E6; VeroE6
Accession CVCL_0574
Resource Identification Initiative To cite this cell line use: Vero C1008 (RRID:CVCL_0574)
Comments Group: Non-human primate cell line.
Group: Vaccine production cell line.
Virology: Susceptible to infection by many viruses. Supports the growth of slowly replicating viruses (ATCC=CRL-1586).
Virology: Susceptible to infection by SARS coronavirus (SARS-CoV). Produces a lytic infection (PubMed=15731278; PubMed=16494729).
Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32020029; PubMed=32511316; PubMed=33389257; PubMed=34339474).
Doubling time: 22 hours (ATCC=CRL-1586).
Derived from site: In situ; Kidney, epithelium; UBERON=UBERON_0004819.
Cell type: Epithelial cell of kidney; CL=CL_0002518.
Species of origin Chlorocebus sabaeus (Green monkey) (Cercopithecus sabaeus) (NCBI Taxonomy: 60711)
Hierarchy Parent: CVCL_0603 (Vero 76)
Children:
CVCL_D7CA (Abeomics Vero ACE2) CVCL_D7CB (Abeomics Vero GFP) CVCL_JX48 (sVero p66)
CVCL_E1F0 (Ubigene Vero E6 ATG7 KO) CVCL_E1F1 (Ubigene Vero E6 GSDME KO) CVCL_E1F2 (Ubigene Vero E6 PIK3C3 KO)
CVCL_E1F4 (Ubigene Vero E6 STAT1 KO) CVCL_E1F6 (Ubigene Vero E6 ZDHHC20 KO) CVCL_A7UJ (Vero E6-high ACE2)
CVCL_XD71 (Vero E6-S) CVCL_C7NK (Vero E6-TMPRSS2-T2A-ACE2) CVCL_YZ66 (Vero E6/NPC1-KO cl.19)
CVCL_C4RQ (VeroE6-Pgp-KO) CVCL_YQ49 (VeroE6/TMPRSS2)
Sex of cell Female
Age at sampling Adult
Category Spontaneously immortalized cell line
Publications
CLPUB00328
Earley E.M., Johnson K.M.
The lineage of Vero, Vero 76 and its clone C1008 in the United States.
(In book chapter) Vero cells: origin, properties and biomedical applications; Simizu B., Terasima T. (eds.); pp.26-29; Department of Microbiology, School of Medicine, Chiba University; Chiba; Japan (1988)
PubMed=15731278; DOI=10.1128/JVI.79.6.3846-3850.2005; PMCID=PMC1075706
Mossel E.C., Huang C., Narayanan K., Makino S., Tesh R.B., Peters C.J.
Exogenous ACE2 expression allows refractory cell lines to supportplication.
J. Virol. 79:3846-3850(2005)
PubMed=16494729; DOI=10.3201/eid1201.050496; PMCID=PMC3291385
Kaye M., Druce J., Tran T., Kostecki R., Chibo D., Morris J., Catton M., Birch C.
SARS-associated coronavirus replication in cell lines.
Emerg. Infect. Dis. 12:128-133(2006)
PubMed=19016439; DOI=10.1002/9780471729259.mca04es11; PMCID=PMC2657228
Ammerman N.C., Beier-Sexton M., Azad A.F.
Growth and maintenance of Vero cell lines.
Curr. Protoc. Microbiol. 11:A.4E.1-A.4E.7(2008)
PubMed=32020029; DOI=10.1038/s41422-020-0282-0; PMCID=PMC7054408
Wang M.-L., Cao R.-Y., Zhang L.-K., Yang X.-L., Liu J., Xu M.-Y., Shi Z.-L., Hu Z.-H., Zhong W., Xiao G.-F.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 30:269-271(2020)
PubMed=32511316; DOI=10.1101/2020.03.02.972935; PMCID=PMC7239045
Harcourt J.L., Tamin A., Lu X.-Y., Kamili S., Kumar-Sakthivel S., Murray J., Queen K., Tao Y., Paden C.R., Zhang J., Li Y., Uehara A., Wang H.-B., Goldsmith C., Bullock H.A., Wang L.-J., Whitaker B., Lynch B., Gautam R., Schindewolf C., Lokugamage K.G., Scharton D., Plante J.A., Mirchandani D., Widen S.G., Narayanan K., Makino S., Ksiazek T.G., Plante K.S., Weaver S.C., Lindstrom S., Tong S.-X., Menachery V.D., Thornburg N.J.
Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.
bioRxiv 2020:972935-972935(2020)
PubMed=33389257; DOI=10.1007/s10096-020-04106-0; PMCID=PMC7778494
Wurtz N., Penant G., Jardot P., Duclos N., La Scola B.
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Eur. J. Clin. Microbiol. Infect. Dis. 40:477-484(2021)
PubMed=34339474; DOI=10.1371/journal.pone.0255622; PMCID=PMC8328321
Pommerenke C., Rand U., Uphoff C.C., Nagel S., Zaborski M., Hauer V., Kaufmann M., Meyer C., Denkmann S.A., Riese P., Eschke K., Kim Y., Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies.
PLoS ONE 16:E0255622-E0255622(2021)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
传代步骤比较传统：倒掉培养液－>PBS洗2遍－>胰酶0.25%消化－>倒掉胰酶－>加培养基－>用吸管吹打均匀－>分瓶－>放置37度，5%CO2孵箱。我的体会是：1、消化时间和实验环境温度也有很大关系，我们实验室条件比较差，不能维持恒温（不过我想大部分实验室目前也还是做不到的）。夏天的时候，消化特别快。但是到了冬天，就很慢，要用手捂老半天。2、消化到什么程度可以，经验很重要，如果每瓶消化都要通过显微镜观察来判断，首先效率太低，而且还很容易消化过头。对光观察培养瓶，当感觉到有些泛白，瓶角有少许细胞
vero（非洲绿猴肾cell):贴壁细胞，以25ml小方瓶为例，培养液用的是MEM。 MEM的配制：10%小牛血清，1%双抗，3%谷氨酰胺，1~1.5%NaHCO3. 传代方法： 1、倒掉培养液，如果细胞脏的话可用PBS洗两次，否则不用。 2.、胰酶0.25%2ml消化1~3分钟，容易消化. 3、倒掉胰酶，加MEM9~12ml,将贴壁细胞摇至悬浮，并用吸管吹匀，一传三或一传四。 4、置37度，5%CO2孵箱。
多年来，国外已成功的研制了采用Vero细胞生产疫苗并获准上市，包括人用狂犬病纯化疫苗、脊髓灰质炎灭活（纯化）疫苗（IPV），并在中国注册或正在注册申请中。在上世纪九十年代后，国产的采用Vero细胞生产的人用狂犬病纯化疫苗、乙型脑炎纯化疫苗、肾综合征出血热纯化疫苗被批准上市。近年来，又有一些企业申请乙型脑炎纯化疫苗、脊髓灰质炎灭活（纯化）疫苗、甲型肝炎灭活疫苗进行临床研究或上市。随着采用Vero细胞生产疫苗种类的增多，并且使用人群扩大到婴幼儿，其细胞残留物质越来越受到关注，已成为我们审评中重点
技术资料